Literature DB >> 27106797

Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients.

Jayakumar Hascitha1, Ramanathan Priya1, Subramani Jayavelu1, Hemavathi Dhandapani1, Ganeshrajah Selvaluxmy2, Shirley Sunder Singh3, Thangarajan Rajkumar4.   

Abstract

OBJECTIVES: Indoleamine 2,3-Dioxygenase (IDO) catalyses the degradation of the essential amino acid tryptophan leading to the production of immunosuppressive Kynurenine. In the present study, we developed a modified method for measurement of Kynurenine/tryptophan (K/T) ratio in the cervical tissue using HPLC and investigated its relationship with the expression of IDO1 and 2 genes in the cervical tumour milieu. DESIGN AND METHODS: Cervical cancer punch biopsy samples of 27 women who presented at the Cancer Institute (WIA) were used for detection of K/T ratio by HPLC as well as expression of IDO1 and 2 at the mRNA level by Realtime PCR after obtaining Institutional ethical committee approval.
RESULTS: The K/T ratio was elevated significantly in cancer cervix samples compared to normal cervix (p<0.05). IDO1 mRNA levels were up-regulated whereas IDO2 mRNA levels were down-regulated in cancer cervix compared to the normal cervix. A positive correlation was observed between IDO1 and K/T (p<0.05) indicating that IDO1 was responsible for the increase in K/T ratio.
CONCLUSION: Our preliminary data indicates that the K/T ratio at the tissue level may be investigated reliably using HPLC, as an indirect measure of IDO1 gene expression and activity.
Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; HPLC; IDO; Kynurenine; Tryptophan

Mesh:

Substances:

Year:  2016        PMID: 27106797     DOI: 10.1016/j.clinbiochem.2016.04.008

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  25 in total

1.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

2.  Correlation between indoleamine 2,3 dioxygenase mRNA and CDKN2A/p16 mRNA: a combined strategy to cervical cancer diagnosis.

Authors:  Mario Cezar Saffi Junior; Ivone da Silva Duarte; Rodrigo Barbosa de Oliveira Brito; Giovana Garcia Prado; Sergio Makabe; Humberto Dellê; Cleber P Camacho
Journal:  Med Oncol       Date:  2016-10-19       Impact factor: 3.064

3.  Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.

Authors:  Hamed Hosseinalizadeh; Mehrdad Mahmoodpour; Ali Akbar Samadani; Mehryar Habibi Roudkenar
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.738

5.  Quantification of IDO1 enzyme activity in normal and malignant tissues.

Authors:  Lijie Zhai; Erik Ladomersky; April Bell; Corey Dussold; Krislyn Cardoza; Jun Qian; Kristen L Lauing; Derek A Wainwright
Journal:  Methods Enzymol       Date:  2019-07-24       Impact factor: 1.600

Review 6.  The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions-Evidence for Estrogen as an Immunomodulator.

Authors:  Jayshree R S
Journal:  Front Cell Infect Microbiol       Date:  2021-04-30       Impact factor: 5.293

7.  A prospective study of pre-diagnostic circulating tryptophan and kynurenine, and the kynurenine/tryptophan ratio and risk of glioma.

Authors:  Claudine M Samanic; Yiyang Yue; David J Cote; Meir J Stampfer; Molin Wang; Adrian McCann; Øivind Midttun; Per Magne Ueland; Stephanie A Smith-Warner; Kathleen M Egan
Journal:  Cancer Epidemiol       Date:  2021-12-03       Impact factor: 2.984

Review 8.  Metabolomics in cancer research and emerging applications in clinical oncology.

Authors:  Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale
Journal:  CA Cancer J Clin       Date:  2021-05-13       Impact factor: 286.130

Review 9.  IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity.

Authors:  Lauren M F Merlo; Laura Mandik-Nayak
Journal:  Clin Med Insights Pathol       Date:  2016-11-21

10.  Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.

Authors:  Yong Qin; Suhendan Ekmekcioglu; Marie-Andrée Forget; Lorant Szekvolgyi; Patrick Hwu; Elizabeth A Grimm; Amir A Jazaeri; Jason Roszik
Journal:  Front Immunol       Date:  2017-06-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.